Cholera toxin breakdowns oral tolerance via activation of canonical NF-κB

Cellular Immunology

Volumn 285, Issue 1-2, 2013, Pages 92-99

  Kim, Kyoung Jin ^a   Kim, Han A ^a,d   Seo, Kook Heon ^b   Lee, Hern Ku ^c   Kang, Bok Yun ^a   Im, Suhn Young ^a  

^a Chonnam National University   (South Korea)

^b Jeollanamdo Biopharmaceutical Research Center   (South Korea)

^c Chonbuk National University Medical School   (South Korea)

^d Gwangju Institute of Science and Technology (GIST)   (South Korea)

Author keywords

Cholera toxin; Mesenteric lymph node; NF B; Oral tolerance; Peyer's patch

Indexed keywords

ADENOSINE DIPHOSPHATE; CHOLERA TOXIN; CYTOKINE; HETERODIMER; I KAPPA B; MESSENGER RNA; OVALBUMIN; PROTEIN P50; SMALL INTERFERING RNA; SYNAPTOTAGMIN I;

ADENOSINE DIPHOSPHATE RIBOSYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; FEEDING; FEMALE; GENE EXPRESSION; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; LYMPH NODE CELL; LYMPHOCYTE PROLIFERATION; LYMPHOID CELL; MESENTERY LYMPH NODE; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PEYER PATCH; PRIORITY JOURNAL;

3-AB; 3-AMINOBENZAMIDE; 5-(AND 6)-CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; CFSE; CHOLERA TOXIN; CT; DC; DENDRITIC CELLS; FBS; FETAL BOVINE SERUM; IL; INTERLEUKIN; MESENTERIC LYMPH NODE; MLN; NF-ΚB; NUCLEAR FACTOR-ΚB; ORAL TOLERANCE; OVA; OVALBUMIN; PCR; PEI; PEYER'S PATCH; POLYETHYLENE IMINE; POLYMERASE CHAIN REACTION; PP; SIRNA; SMALL INTERFERING RNA; TNF; TUMOR NECROSIS FACTOR;

ANIMALS; BENZAMIDES; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; CHOLERA TOXIN; ENZYME INHIBITORS; FEMALE; IMMUNE TOLERANCE; IMMUNOGLOBULIN A; LYMPH NODES; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MOUTH MUCOSA; NF-KAPPA B; NF-KAPPA B P50 SUBUNIT; NIACINAMIDE; OVALBUMIN; PEYER'S PATCHES; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSCRIPTION FACTOR RELA; VITAMIN B COMPLEX;

EID: 84885741245     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2013.09.006     Document Type: Article

References (44)

1. Pabst O., Mowat A.M. Oral tolerance to food protein. Mucosal Immunology 2012, 5:232-239.
2. Faria A.M., Weiner H.L. Oral tolerance: therapeutic implications for autoimmune diseases. Clinical and Developmental Immunology 2006, 13:143-157.
3. Weiner H.L. Current issues in the treatment of human diseases by mucosal tolerance. Annals of the New York Academy of Sciences 2004, 1029:211-224.
4. Williams N.A., Hirst T.R., Nashar T.O. Immune modulation by the cholera-like enterotoxins: from adjuvant to therapeutic. Immunology Today 1999, 20:95-101.
5. Ouchi N., Kihara S., Arita Y., Okamoto Y., Maeda K., Kuriyama H., Hotta K., Nishida M., Takahashi M., Muraguchi M., Ohmoto Y., Nakamura T., Yamashita S., Funahashi T., Matsuzawa Y. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000, 102:1296-1301.
6. Delgado M., Ganea D. Inhibition of endotoxin-induced macrophage chemokine production by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in vitro and in vivo. Journal of Immunology 2001, 167:966-975.
7. Cong Y., Weaver C.T., Elson C.O. The mucosal adjuvanticity of cholera toxin involves enhancement of costimulatory activity by selective up-regulation of B7.2 expression. Journal of Immunology 1997, 159:5301-5308.
8. Lycke N., Holmgren J. Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens. Immunology 1986, 59:301-308.
9. Gardby E., Wrammert J., Schon K., Ekman L., Leanderson T., Lycke N. Strong differential regulation of serum and mucosal IgA responses as revealed in CD28-deficient mice using cholera toxin adjuvant. Journal of Immunology 2003, 170:55-63.
10. Holmgren J., Czerkinsky C., Lycke N., Svennerholm A.M. Mucosal immunity: implications for vaccine development. Immunobiology 1992, 184:157-179.
11. Marks E., Helgeby A., Andersson J.O., Schon K., Lycke N.Y. CD4(+) T-cell immunity in the female genital tract is critically dependent on local mucosal immunization. European Journal of Immunology 2011, 41:2642-2653.
12. George Chandy A., Hultkrantz S., Raghavan S., Czerkinsky C., Lebens M., Telemo E., Holmgren J. Oral tolerance induction by mucosal administration of cholera toxin B-coupled antigen involves T-cell proliferation in vivo and is not affected by depletion of CD25+ T cells. Immunology 2006, 118:311-320.
13. Elson C.O., Ealding W. Cholera toxin feeding did not induce oral tolerance in mice and abrogated oral tolerance to an unrelated protein antigen. Journal of Immunology 1984, 133:2892-2897.
14. Cox E., Verdonck F., Vanrompay D., Goddeeris B. Adjuvants modulating mucosal immune responses or directing systemic responses towards the mucosa. Veterinary Research 2006, 37:511-539.
15. Eriksson K., Fredriksson M., Nordstrom I., Holmgren J. Cholera toxin and its B subunit promote dendritic cell vaccination with different influences on Th1 and Th2 development. Infection and Immunity 2003, 71:1740-1747.
16. Kroghsbo S., Christensen H.R., Frokiaer H. Experimental parameters differentially affect the humoral response of the cholera-toxin-based murine model of food allergy. International Archives of Allergy and Immunology 2003, 131:256-263.
17. Snider D.P., Marshall J.S., Perdue M.H., Liang H. Production of IgE antibody and allergic sensitization of intestinal and peripheral tissues after oral immunization with protein Ag and cholera toxin. Journal of Immunology 1994, 153:647-657.
18. van Ginkel F.W., Jackson R.J., Yoshino N., Hagiwara Y., Metzger D.J., Connell T.D., Vu H.L., Martin M., Fujihashi K., McGhee J.R. Enterotoxin-based mucosal adjuvants alter antigen trafficking and induce inflammatory responses in the nasal tract. Infection and Immunity 2005, 73:6892-6902.
19. Armstrong M.E., Lavelle E.C., Loscher C.E., Lynch M.A., Mills K.H. Proinflammatory responses in the murine brain after intranasal delivery of cholera toxin: implications for the use of AB toxins as adjuvants in intranasal vaccines. The Journal of Infectious Diseases 2005, 192:1628-1633.
20. Alving C.R. Lipopolysaccharide, lipid A, and liposomes containing lipid A as immunologic adjuvants. Immunobiology 1993, 187:430-446.
21. Williamson E., Westrich G.M., Viney J.L. Modulating dendritic cells to optimize mucosal immunization protocols. Journal of Immunology 1999, 163:3668-3675.
22. Bromander A., Holmgren J., Lycke N. Cholera toxin stimulates IL-1 production and enhances antigen presentation by macrophages in vitro. Journal of Immunology 1991, 146:2908-2914.
23. Lycke N., Bromander A.K., Ekman L., Karlsson U., Holmgren J. Cellular basis of immunomodulation by cholera toxin in vitro with possible association to the adjuvant function in vivo. Journal of Immunology 1989, 142:20-27.
24. Vallabhapurapu S., Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. Annual Review of Immunology 2009, 27:693-733.
25. Blumberg R.S., Pitman R.S., Taylor C.T., Colgan S.P. Cholera toxin potentiates influences of IFN-gamma through activation of NF-kappaB and release of tumor necrosis factor-alpha. Journal of Interferon & Cytokine Research: the Official Journal of the International Society for Interferon and Cytokine Research 2005, 25:209-219.
26. Kawamura Y.I., Kawashima R., Shirai Y., Kato R., Hamabata T., Yamamoto M., Furukawa K., Fujihashi K., McGhee J.R., Hayashi H., Dohi T. Cholera toxin activates dendritic cells through dependence on GM1-ganglioside which is mediated by NF-kappaB translocation. European Journal of Immunology 2003, 33:3205-3212.
27. Ando T., Hatsushika K., Wako M., Ohba T., Koyama K., Ohnuma Y., Katoh R., Ogawa H., Okumura K., Luo J., Wyss-Coray T., Nakao A. Orally administered TGF-beta is biologically active in the intestinal mucosa and enhances oral tolerance. The Journal of Allergy and Clinical Immunology 2007, 120:916-923.
28. Han S.J., Ko H.M., Choi J.H., Seo K.H., Lee H.S., Choi E.K., Choi I.W., Lee H.K., Im S.Y. Molecular mechanisms for lipopolysaccharide-induced biphasic activation of nuclear factor-kappa B. The Journal of Biological Chemistry 2002, 277:44715-44721.
29. Kim H.A., Kim K.J., Yoon S.Y., Lee H.K., Im S.Y. Glutamine inhibits platelet-activating factor-mediated pulmonary tumour metastasis. European Journal of Cancer 2012, 48:1730-1738.
30. Ghosh S., May M.J., Kopp E.B. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annual Review of Immunology 1998, 16:225-260.
31. Li Z.W., Chu W., Hu Y., Delhase M., Deerinck T., Ellisman M., Johnson R., Karin M. The IKKbeta subunit of IkappaB kinase (IKK) is essential for nuclear factor kappaB activation and prevention of apoptosis. The Journal of Experimental Medicine 1999, 189:1839-1845.
32. Senftleben U., Li Z.W., Baud V., Karin M. IKKbeta is essential for protecting T cells from TNFalpha-induced apoptosis. Immunity 2001, 14:217-230.
33. Dejardin E., Droin N.M., Delhase M., Haas E., Cao Y., Makris C., Li Z.W., Karin M., Ware C.F., Green D.R. The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity 2002, 17:525-535.
34. Senftleben U., Cao Y., Xiao G., Greten F.R., Krahn G., Bonizzi G., Chen Y., Hu Y., Fong A., Sun S.C., Karin M. Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science 2001, 293:1495-1499.
35. Hayden M.S., Ghosh S. Signaling to NF-kappaB. Genes & Development 2004, 18:2195-2224.
36. Kato H., Fujihashi K., Kato R., Yuki Y., McGhee J.R. Oral tolerance revisited: prior oral tolerization abrogates cholera toxin-induced mucosal IgA responses. Journal of Immunology 2001, 166:3114-3121.
37. Westlund J., Livingston M., Fahlen-Yrlid L., Oldenborg P.A., Yrlid U. CD47-deficient mice have decreased production of intestinal IgA following oral immunization but a maintained capacity to induce oral tolerance. Immunology 2012, 135:236-244.
38. Shih V.F., Davis-Turak J., Macal M., Huang J.Q., Ponomarenko J., Kearns J.D., Yu T., Fagerlund R., Asagiri M., Zuniga E.I., Hoffmann A. Control of RelB during dendritic cell activation integrates canonical and noncanonical NF-kappaB pathways. Nature Immunology 2012, 13:1162-1170.
39. Ardeshna K.M., Pizzey A.R., Devereux S., Khwaja A. The PI3 kinase, p38 SAP kinase, and NF-kappaB signal transduction pathways are involved in the survival and maturation of lipopolysaccharide-stimulated human monocyte-derived dendritic cells. Blood 2000, 96:1039-1046.
40. Ouaaz F., Arron J., Zheng Y., Choi Y., Beg A.A. Dendritic cell development and survival require distinct NF-kappaB subunits. Immunity 2002, 16:257-270.
41. Le Page C., Sanceau J., Drapier J.C., Wietzerbin J. Inhibitors of ADP-ribosylation impair inducible nitric oxide synthase gene transcription through inhibition of NF kappa B activation. Biochemical and Biophysical Research Communications 1998, 243:451-457.
42. Ishibashi Y., Nishikawa A. Role of nuclear factor-kappa B in the regulation of intercellular adhesion molecule 1 after infection of human bronchial epithelial cells by Bordetella pertussis. Microbial Pathogenesis 2003, 35:169-177.
43. Tonon S., Goriely S., Aksoy E., Pradier O., Del Giudice G., Trannoy E., Willems F., Goldman M., De Wit D. Bordetella pertussis toxin induces the release of inflammatory cytokines and dendritic cell activation in whole blood: impaired responses in human newborns. European Journal of Immunology 2002, 32:3118-3125.
44. Jajoo S., Mukherjea D., Pingle S., Sekino Y., Ramkumar V. Induction of adenosine A1 receptor expression by pertussis toxin via an adenosine 5'-diphosphate ribosylation-independent pathway. The Journal of Pharmacology and Experimental Therapeutics 2006, 317:1-10.